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ABSTRACT
Background and study aims The aim of thi systematic re-
view and consensus report is to standardize the practice of
endoscopic ultrasound (EUS-guided needle-based confocal
laser endomicroscopy (nCLE) for pancreatic cystic lesion
(PCL) evaluation.
Methods We performed an international, systematic, evi-
dence-based review of the applications, outcomes, proce-
dural processes, indications, training, and credentialing of
EUS-nCLE in management of PCLs. Based on available clini-
cal evidence, preliminary nCLE consensus statements
(nCLE-CS) were developed by an international panel of 15
experts in pancreatic diseases. These statements were
then voted and edited by using a modified Delphi approach.
An a priori threshold of 80% agreement was used to estab-
lish consensus for each statement.
Results Sixteen nCLE-CS were discussed. Thirteen (81%)
nCLE-CS reached consensus addressing indications (non-
communication PCL meeting criteria for EUS-FNA or with
prior non-diagnostic EUS-FNA), diagnostic outcomes (im-
proved accuracy for mucinous PCLs and serous cystadeno-
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Introduction
Over the last decade, Confocal Laser Endomicroscopy (CLE) has
emerged as a promising technology to overcome the inherent
limitations of endoscopic sampling techniques by providing
both the endoscopist and the pathologist, real-time imaging
of tissue and vascular microstructures. Needle-based confocal
laser endomicroscopy (nCLE) enables real-time in vivo micro-
scopic imaging during endoscopic ultrasound-guided fine nee-
dle aspiration (EUS-FNA) with the potential to improve the dif-
ferentiation of various types of pancreatic lesions [1, 2].
The first study used prototype probes and demonstrated the
technical feasibility, established an imaging protocol, and as-
sessed the safety of EUS-nCLE [3]. A subsequent preliminary
study targeted the development of descriptive criteria for im-
age interpretation and classification of the nCLE findings for
pancreatic masses, pancreatic cystic lesions (PCLs), and lymph
nodes [4]. Following these initial feasibility studies, several
multicenter trials were conducted [5–15].
Overall, more than 600 patients have been enrolled since
2011 in these studies involving EUS-nCLE evaluation of PCLs
(▶Fig. 1).
In 2015, an initiative was announced to establish the first
consensus report on probe-based confocal laser endomicrosco-
py (pCLE) pertaining to four different gastrointestinal patholo-
gies (Barrett’s esophagus, biliary strictures, colorectal lesions,
and inflammatory bowel diseases) [16]. The present consensus
document reports on proposed indications and use of EUS-
guided nCLE for evaluation of PCLs. It aims to provide guidance
to nCLE users and to other interested healthcare professionals
on standardization of practice, recommendations on training,
and credentialing for the procedure.
Methods
The principal steps in the methodology included: (1) selection
of the consensus group; (2) development of draft statements;
(3) systematic review of the literature to identify evidence to
support consensus statements; (4) voting on draft statements
to reach consensus; and (5) grading of the strength and quality
of the evidence, and strength of the recommendations using
accepted a priori criteria.
All invited panelists on the consensus group had to comply
with the following criteria:
1. Be either an advanced nCLE user or an expert in endoscopy
of pancreatic pathology for at least two years prior to parti-
cipation in the consensus process;
2. Have published or lectured in international meetings on
nCLE applications or pancreatic pathology;
3. Agree to review literature and participate in the voting pro-
cess.
The clinical evidence considered to establish the statements in
this consensus was collected through literature search and re-
view of published articles available on PubMed/MEDLINE, Em-
base, Cochrane Database, and Google Scholar, from January 1,
2000 to May 31, 2017. The following search terms were used:
CLE, confocal, confocal endomicroscopy, endomicroscopy,
needle-based confocal laser endomicroscopy for a pancreatic
indication, and PCLs. No language restriction was applied.
Four consensus meetings attended by the members of the
panel were conducted between April 2015 and May 2017
(▶Fig. 2). Additional approval from members was obtained
electronically to accommodate individual study (CONTACT II
and INDEX) updates till June 30, 2019 (▶Fig. 2).
A compiled revision of the statements was prepared by the
chairmen and shared with the members, who independently
voted on each statement via an electronic web-based survey
(SurveyMonkey.com) regarding the grade of clinical evidence
and their level of agreement or disagreement. Participants
could refuse to vote for a statement if they believed that they
were not familiar with the topic to avoid any bias. The classifica-
tion used for agreement level and grade of evidence (▶Table 1)
was available to all the participants. For grading the agree-
ments, a five-point Likert scale was used (▶Table 1) [17]. Con-
sensus was achieved when 80% or more of voting members in-
dicated “agree completely” or “agree with some reservation.”
In all other cases, the statements were rejected.
Statistical analysis
Diagnostic outcomes were pooled through a random-effects
model based on DerSimonian and Laird test, and summary esti-
mates were expressed in terms of rate and 95% confidence in-
terval (CI). Comparison between EUS-nCLE and EUS-FNA was
based on a random-effects model. Chi-square and I2 tests
were used across studies for comparison of the percentage of
variability attributable to heterogeneity beyond chance. The
analyses were performed by using the “metaphor” and “meta”
packages in R software (R Foundation for Statistical Computing,
Vienna, Austria).
Results
A total of 16 statements were proposed. Among these, 13
(81%) nCLE-CS reached consensus, while three (19%) were re-
jected. The level of agreement and the grade of evidence for
each statement are reported in ▶Table 2.
mas with substantial interobserver agreement of image
patterns), low incidence of adverse events (fluorescein-
associated and pancreatitis), procedural processes (nCLE
duration, manipulation of needle with probe), and training
(physician knowledge and competence).
Conclusion Based on a high level of agreement pertaining
to expert consensus statements, this report standardizes
the practice of EUS-nCLE. EUS-nCLE should be systematical-
ly considered when EUS-FNA is indicated for PCL evaluation.
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▶ Fig. 2 Methodology workflow.
▶Table 1 Classification of evidence levels and voting on recommen-
dation/agreement level with descriptions.
Evidence level/agreement level descriptions
Evidence level
I-A Evidence frommeta-analysis of RCTs
I-BE vidence from at least 1 RCT
II-AE vidence from at least 1 controlled study without randomization
II-BE vidence from at least 1 other type of quasi-experimental study
III Evidence from non-experimental descriptive studies, such as com-
parative studies, correlation studies, and case-control studies
IV Evidence from expert committee reports or opinions or clinical
experience of respected authorities, or both
Voting on recommendation / Agreement level
AA Agree strongly
A Agree with minor reservation
N Agree with major reservation
D Disagree with reservation
DD Disagree completely
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▶Table 2 nCLE statement agreement and evidence level poll result summary.
Statement
#
Statement AA+A Agreement Results
1.1 nCLE can improve the diagnosis of non-communicating pancreatic cystic lesions compar-
ed to current standard of care
Agreement AA: 53%, A: 47%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
Evidence I-A: 6.7%, I-B: 0.0%, II-A: 66.7%, II-B: 13.3 %, III: 13.3 %, or IV: 0.0% II-A
1.2 nCLE is reliable to differentiate between mucinous and non-mucinous pancreatic cystic
lesions
Agreement AA: 47%, A: 47%, N: 7%, D: 0%, DD: 0% AA+A: 94% Adopted
Evidence I-A: 0.0%, I-B: 6.7%, II-A: 66.7%, II-B: 13.3 %, III: 13.3 %, or IV: 0.0% II-A
1.3 nCLE is reliable to diagnose SCA accurately
Agreement AA: 67%, A: 33%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
Evidence I-A: 6.7%, I-B: 6.7% II-A: 60.0%, II-B: 20.0%, III: 6.7 %, or IV: 0.0% II-A
1.4 nCLE is highly accurate to diagnose cystic NEN
Agreement AA: 20%, A: 20%, N: 53%, D: 7%, DD: 0% AA+A: 46% Rejected
Evidence I-A: 0.0%, I-B: 6.7%, II-A: 6.7 %, II-B: 46.7%, III: 33.3%, or IV: 6.7% II-B
1.5 Inter-observer agreement of nCLE for the diagnosis of cystic lesion is substantial
Agreement AA: 40%, A: 53%, N: 7%, D: 0%, DD: 0% AA+A: 93% Adopted
Evidence I-A: 6.7%, I-B: 13.3% II-A: 60.0%, II-B: 0.0%, III: 20.0%, or IV: 0.0% II-A
2.1 The incidence of adverse events associated with intravenous fluorescein injection is ex-
tremely low
Agreement AA: 93%, A: 7%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
Evidence I-A: 20.0%, I-B: 0.0% II-A: 60.0%, II-B: 0.0%, III: 20.0%, or IV: 0.0% II-A
2.2 The largest surface area of the cyst epitheliummust be examined, however the procedure
must be stopped once diagnostic nCLE features of a PCL are observed
Agreement AA: 93%, A: 0%, N: 7%, D: 8%, DD: 0% AA+A: 93% Adopted
Evidence I-A: 6.7%, I-B: 6.7% II-A: 60.0%, II-B: 13.3%, III: 20.0, or IV: 20.0% IV
2.3 Duration of nCLE procedure should not exceed 6 minutes
Agreement AA: 40%, A: 47%, N: 13%, D: 0%, DD: 0% AA+A: 87% Adopted
Evidence I-A: 0.0%, I-B: 6.7%, II-A: 13.3%, II-B: 46.7 %, III: 20.0 %, or IV: 13.3% IV
2.4 Needle and probe should be manipulated with caution to minimize disruption of the cyst
epithelium
Agreement AA: 67%, A: 26%, N: 7%, D: 0%, DD: 0% AA+A: 93% Adopted
Evidence I-A: 0.0%, I-B: 13.3%, II-A:33.3%, II-B: 20.0 %, III: 6.7%, or IV: 26.7% IV
2.5 The onsite presence of cytopathologist can facilitate nCLE image interpretation
Agreement AA: 7%, A: 33%, N: 33%, D: 20%, DD: 7% AA+A: 40% Rejected
Evidence I-A: 0.0%, I-B: 6.7%, II-A: 0.0 %, II-B: 0.0%, III: 53.3%, or IV: 40.0% IV
3.1 nCLE is indicated in patients with indeterminate non-communicating cysts when EUS- FNA
is indicated
Agreement AA: 60%, A: 33%, N: 7%, D: 0%, DD: 0% AA+A: 93% Adopted
Evidence I-A: 6.7%, I-B: 6.7% II-A: 53.3%, II-B: 6.7 %, III: 6.7%, or IV: 20.0% II-A
3.2 nCLE is indicated when a pancreatic cyst remains indeterminate despite previous EUS-FNA
Agreement AA: 60%, A: 27%, N: 13%, D: 0%, DD: 0% AA+A: 87% Adopted
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Consensus statements
Outcomes of EUS-nCLE
nCLE can improve the diagnosis of non-communicating pan-
creatic cystic lesions compared to current standard of care
(Statement 1).
In the absence of histology, cyst fluid CEA (Carcinoembryo-
nic Antigen) and cytology are considered standard of care in
the differential diagnosis of PCLs [18]. CEA values of≥192ng/
mL signify a mucinous PCL, however sensitivity and specificity
are sub-optimal [19] (0.73 and 0.84 respectively). Moreover,
the optimal cut-off value of CEA varies and ranges from 30ng/
mL to 480ng/mL [20–23]. Spurious fluctuations of intra-indi-
vidual CEA levels occur in approximately 20% of patients [24].
Cytology is accurate in only 50% to 60% of cases due to scant
cellularity of cyst fluid [19, 25]. EUS-FNA cytology yield for ser-
ous cystadenomas (SCA) is very low and hence a cytopathologi-
cal diagnosis is difficult to establish [26]. Preliminary studies in
EUS-nCLE have demonstrated improved diagnostic accuracy in
the detection of mucinous PCLs compared to current standard
of practice (CEA and cytology) [6, 9,27,28]. In four clinical trials
evaluating EUS-nCLE (▶Table3, ▶Fig. 3, ▶Fig. 4), the pooled
diagnostic yield and accuracy of nCLE were significantly higher
than those of CEA; 88% (82–93, 95% CI) and 77% (64–86, 95%
CI) for yield (odds ratio 2.84 (1.15–7.01, 95% CI) with P= .02)
and 96% (92–98, 95% CI) and 64% (57–71, 95% CI) accuracy
(odds ratio 13.89 (5.72–33.69, 95% CI) with P < .0001), respec-
tively. A recent meta-analysis also demonstrated an EUS-nCLE
pooled diagnostic accuracy of 89% (84–93, 95% CI) which was
significantly higher than that of EUS-FNA (odds ratio 3.94
(1.58–9.82, 95% CI)) [29].
nCLE is reliable to differentiate between mucinous and
non-mucinous pancreatic cystic lesions (Statement 2).
While papillary projections and/or dark rings (cross-section-
al view of papillae) during nCLE imaging represent the villous
pattern of intraductal papillary mucinous neoplasms (IPMNs),
the horizon type epithelial bands represent the lining of muci-
nous cystic neoplasms (MCNs). A summary of the different
studies evaluating the diagnostic performance of nCLE for dif-
ferentiation of mucinous versus non-mucinous PCLs is shown
in ▶Table 4 and ▶Fig. 5. While the pooled specificity was 97%
(92–99% 95%CI), sensitivity was 95% in two of the largest trials
[14, 15] with the highest number of subjects with surgical his-
topathology as diagnostic gold standard. In their meta-analysis,
Facciorusso et al. [29] indicated that the diagnostic accuracy
for mucinous lesions reached 91% (86%-97%, 95% CI).
nCLE is reliable to diagnose serous cystadenoma (SCA)
accurately (Statement 3).
For diagnosing SCAs, a pooled analysis has demonstrated
that cyst fluid CEA<5ng/mL has a specificity of 95% albeit a
low sensitivity of 50% [30]. Importantly however, cystic neu-
roendocrine neoplasms (NEN) and IPMNs were not included in
this analysis.
Histologically, SCAs are unique and are characterized by
dense subepithelial capillary vascularization [6, 9,28]. In several
studies [6, 9,10] this histological [31] . The diagnostic perform-
ance of this particular nCLE feature was then assessed in three
clinical studies [6, 9,10] (▶Table 4, ▶Fig. 6) with an almost per-
fect pooled specificity (97%, 92–99% 95%CI) and sensitivity
over 95% in two of the studies [6, 14]. One study also showed
a diagnostic performance for nCLE significantly higher than
that of CEA ( < 5ng/mL) for predicting benign lesions with areas
under the receiver operating characteristic (AUROC) of 96%
and 84% for nCLE and CEA (P <0.05), respectively [14].
▶Table 2 (Continuation)
Statement
#
Statement AA+A Agreement Results
Evidence I-A: 0.0%, I-B: 13.3%, II-A: 6.7%, II-B: 6.7%, III: 46.7%, or IV: 26.7% II-A
3.3 Repeat nCLE on subsequent follow-up procedures should be routinely performed
Agreement AA: 00%, A: 0%, N: 0%, D: 7%, DD: 93% DD+D: 93% Rejected
Evidence I-A: 6.7%%, I-B: 0.0%, II-A: 6.7%%, II-B: 0.0%, III: 20.0%, or IV: 66.7% IV
4.1 Physicians are expected to have a good understanding of pancreatic cystic lesions, and
procedural indications and contraindications for EUS-nCLE
Agreement AA: 100%, A: 0%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
4.2 Trainees in EUS-nCLE of PCLs need to be fully competent in pancreatic EUS and EUS-FNA
Agreement AA: 100%, A: 0%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
4.3 Trainees should learn how to obtain optimal nCLE images of the intracystic epithelium to
achieve satisfactory images
Agreement AA: 100%, A: 0%, N: 0%, D: 0%, DD: 0% AA+A: 100% Adopted
nCLE, needle-based confocal laser endomicroscopy; PCL, pancreatic cystic lesion; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration
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nCLE is highly accurate to diagnose cystic NEN
(Statement 4).
Napoleon et al. [9] also reported a new diagnostic nCLE cri-
terion of “dark spots surrounded by grey areas” in cystic NEN
[9]. Both Karia et al. [32] and a case report published by Kamboj
et al. [33] confirmed this observation and reported visualiza-
tion of well-demarcated clusters of cells with surrounding areas
of fibrosis and vascularity. In a recent multicenter, prospective,
controlled study [14] (CONTACT-II), seven NENs were included
in the cohort of PCLs and the sensitivity, specificity, and accura-
cy for their diagnosis with the above criterion was 100%, 95%,
and 98% respectively. In addition, Krishna et al. (INDEX study)
▶Table 3 Diagnostic yield and accuracy for diagnosis of mucinous pancreatic cystic lesions using carcinoembryonic antigen (CEA) (≥192ng/mL),
nCLE, and EUS.
Publica-
tion year
First author Study
name
N1 nDD 1
(surgery)
CEA
yield1
EUS
yield1
nCLE
yield1
CEA
ACC11
EUS
ACC1
nCLE
ACC1
2013 Konda, VJ. [27] INSPECT  66  57 (14) 62% NA  89% NA NA 71%2
2015 Nakai, Y. [28] DETECT  30  18 (2) 93% 100% 100% 61% 73% 87%
2019 Napoleon, B. [14] CONTACT II 206  78 (39) 71%3  47%3  91%3 78%3 81%3 97%3
2020 Krishna, S. G. [15] INDEX 144 113 (65) 82% NA  84% 70%3 NA 97%4
1 N represents the total number of patients. Surgery is the number of patients with pancreatic surgery. CEA, carcinoembryonic antigen; nCLE, needle-based confocal
laser endomicroscopy; EUS, endoscopic ultrasound; nDD: Patients with definitive diagnosis (histology from surgery and/or cytopathology); ACC, diagnostic accu-
racy; yield, diagnostic yield; NA, not available.
2 Calculated on a subpopulation of 31 patients (26 patients served for criteria identification).
3 Calculated on a subpopulation of 78 patients for which definitive diagnostic was reached either based on surgery or on cytohistology
4 Calculated on a subpopulation of 65 patients for which definitive diagnostic was reached either based on surgery.
Study year Events Total Diagnostic yield 95% CI
Konda 2013 59 66 0.89  [0.79; 0.96]
Nakai 2015 30 30 1.00 [0.88; 1.00]
Napoleon 2019 71 78 0.91 [0.82; 0.96]
Krishna 2020 121 144 0.84 [0.77; 0.90]
Random effects model  0.88 [0.82; 0.93]
Heterogeneity: I2 = 39%, τ2= 0.1055, χ23 = 4.95 (P = 0.18)
a
b
 nCLE  CEA Weight Weight
Study Events Total Events Total Odds ratio OR 95% CI (fixed) (random)
Konda 2013 59 66 42 66 4.82 [1.90; 12.21] 15.5% 28.9%
Nakai 2015 30 30 28 30 5.35 [0.25; 116.31] 1.6% 7.1%
Napoleon 2019 71 78 55 78 4.24 [1.70; 10.60] 17.2% 29.1%
Krishna 2020 121 144 118 144 1.16 [0.63; 2.15] 65.7% 34.9%
Fixed effect model  318  318 2.32 [1.52; 3.56] 100.0% – P= 0.0001
Random effects model     2.84 [1.15; 7.01] – 100.0% P=0.023
Heterogeneity: I2 = 67%, τ2= 0.5075, P = 0.03
c
Study year Events Total Diagnostic yield 95% CI
Konda 2013 42 66 0.64 [0.51; 0.75]
Nakai 2015 28 30 0.93 [0.78; 0.99]
Napoleon 2019 55 78 0.71 [0.59; 0.80]
Krishna 2020 118 144 0.82 [0.75; 0.88]
Random effects model   0.77 [0.64; 0.86]
Heterogeneity: I2 = 78%, τ2= 0.2781, χ23 =13.35 (P < 0.01)
0.60.40.2 0.8 1
10.10.01 10 100
0.60.40.2 0.8 1
nCLE Diagnostic yield
CEA Diagnostic yield
▶ Fig. 3 Pooled diagnostic yields of a needle-based confocal laser endomicroscopy (nCLE) and b CEA (carcinoembryonic antigen) for pancreatic
cyst lesions diagnosis. Meta-analysis comparing diagnostic yields of nCLE and CEA (c). OR, odds ratio.
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correlated in vivo and ex vivo endomicroscopic images of re-
sected cystic-NENS in which dark clusters or trabeculae of cells
separated by cystic stroma were observed that corresponded
with histological biopsies showing well-differentiated NENs
[31]. In the INDEX study in which there were six patients with
NEN, a trabecular nCLE pattern revealed a sensitivity, specifici-
ty, and accuracy of 100% each, respectively [13].
Inter-observer agreement of nCLE for the diagnosis of cystic
lesion is substantial (Statement 5).
Four studies [9, 10,32,34] have assessed inter-observer Aar-
eement (IOA) for nCLE criteria (▶Table5) in 77 patients (includ-
ing two IOAs, internal and external observers) on the INDEX
study population by Krishna et al. [10]. All studies were con-
ducted with blinded reviewers. Except for the study of Karia et
al. [32], specific and global IOAs were substantial or almost per-
fect (> 0.60), for mucinous lesions, SCA and PC. A notable lim-
itation for this latter study [32] was the low number of patients
with a definitive diagnosis (8 patients) and the low confidence
level for the final diagnosis (53%). This study also had a lower
IOA (kappa 0.04 to 0.22) when compared to the three other
studies [9, 10, 34]. The image criteria assessed were villi, dark
clumps, reticular pattern, acinar cells pattern, and debris,
which are very different and lacked refinement compared to
the validated nCLE characteristics that includes papillary fronds
for IPMNs, epithelial bands for MCNs, bright particles on a dark
background for pseudocysts, and superficial vascular network
or fern pattern for SCAs.
Moreover, the image criteria used by Karia et al. [32] are not
specific to differentiate PCLs. Intra-observer reliability (IORs)
was addressed by the two IOR studies (internal and external ob-
servers) using the INDEX-study population [10, 34] IORs were
reported for all nCLE criteria as substantial ranging from 0.68
to 0.78 for nCLE naïve blinded reviewers (n =6) and as almost
perfect (κ ranging from 0.85 to 0.91) among six blinded nCLE
experts (experience >30 nCLE cases) [10].
EUS-nCLE procedure and technique
The incidence of adverse events associated with intrave-
nous fluorescein injection is extremely low (Statement 6).
The risks associated with intravenous (IV) fluorescein injec-
tion are extremely low (<0.01%) [35]. The most common ad-
verse event (AE) is hypotension (70%) followed by nausea and
vomiting (60%) [35]. Although risk of anaphylaxis is rare, it is
imperative to discuss it with the patient prior to the procedure
[35]. None of the nCLE studies reported AEs related to intrave-
nous (IV) fluorescein administration.
Study year Events Total Diagnostic accuracy 95% CI
Nakai 2015 26 28 0.93 [0.76; 0.99]
Napoleon 2019 69 71 0.97 [0.90; 1.00]
Krishna 2020 63 65 0.97 [0.89; 1.00]
Random effects model   0.96 [0.92; 0.98]
Heterogeneity: I2 = 0%, τ2= 0, χ22 = 1.10 (P = 0.58)
a
b
 nCLE  CEA   Weight Weight
Study Events Total Events Total Odds ratio OR 95% CI (fixed) (random)
Nakai 2015 26 28 17 28 8.41 [1.65; 42.76] 31.6% 29.7%
Napoleon 2019 69 71 43 71 22.47 [5.09; 99.11] 31.5% 35.7%
Krishna 2020 63 65 46 65 13.01 [2.89; 58.65] 36.8% 34.6%
Fixed effect model  164  164 14.54 [6.04; 35.01] 100.0% – P <0.0001
Random effects model     13.89 [5.72; 33.69] – 100.0% P <0.0001
Heterogeneity: I2 = 0%, τ2= 0, P = 0.67
c
Study year Events Total Diagnostic accuracy 95% CI
Nakai 2015 17 28 0.61 [0.41; 0.78]
Napoleon 2019 43 71 0.61 [0.48; 0.72]
Krishna 2020 46 65 0.71 [0.58; 0.81]
Random effects model   0.64 [0.57; 0.71]
Heterogeneity: I2 = 0%, τ2= 0, χ22 =1.76 (P = 0.41)
0.60.40.2 0.8 1
10.1 0.5 2 10
0.60.40.2 0.8 1
nCLE Diagnostic accuracy
CEA Diagnostic accuracy
▶ Fig. 4 Pooled diagnostic accuracies of a needle-based confocal laser endomicroscopy (nCLE) and b CEA (carcinoembryonic antigen) for pan-
creatic cyst lesions diagnosis. c Meta-analysis comparing diagnostic accuracies of nCLE and CEA. OR, odds ratio.
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The largest surface area of the cyst epithelium must be ex-
amined, however, the procedure must be stopped once di-
agnostic nCLE features of a PCL are observed (Statement 7).
To reduce risk of post-procedural acute pancreatitis, it is re-
commended that the nCLE exam should be as short as possible
with a minimum of catheter manipulation. Based on expert opi-
nion, as soon as a diagnostic nCLE criterion is observed, the
exam should be stopped and the probe removed [36].
Duration of nCLE procedure should not exceed 6 minutes
(Statement 8).
Details of the AE risks (overall risk 4.50% (95% confidence in-
terval [CI] 2.44%-6.40%) that occurred in the major trials using
EUS-nCLE for evaluation of PCLs are shown in ▶Table 6 and
▶Fig. 7. The main risk was post-procedural acute pancreatitis.
The highest rate was reported in the DETECT study (6.6%) com-
bining Spyglass cystoscopy and nCLE imaging in the same pro-
cedure. Among a total of 514 patients who have undergone
EUS-nCLE [9, 11, 14, 15, 27, 28, 32], a total of 15 subjects devel-
oped post-procedure acute pancreatitis with an estimated
pooled risk of 2.92% (95% CI 1.6%–5.0%) with only one severe
case [37] and a global AE pooled rate of 4.50% (95% CI 3.0%–
6.6%). This is similar to the pooled pancreatitis rate of 1.63%
(95% CI 0.55%–3.81%) and global AE pooled rate of 5.48%
(95% CI 0.88%–13.64%) from a recently published meta-analy-
sis including five studies (n =242 patients) evaluating morbidity
associated with EUS-guided FNA for PCLs performed using a
19G needle [38].
A correlation between mean nCLE procedure duration and
pancreatitis rate (Pearson correlation=0.86, P=0.03) was no-
ticed when including the six published studies [9, 11, 14, 15,
27, 28, 32] reported in ▶Table6.
Nevertheless in the latest update of the INDEX study [15],
there was no difference in mean duration of nCLE comparing
subjects with and without post-procedural acute pancreatitis
(mean 6.0 vs. 7.3 minutes, P=0.33). In summary, reducing
EUS-nCLE image acquisition time to 6 minutes or less should
decrease risk of post-procedural acute pancreatitis, but these
data remain to be confirmed. In the meta-analysis from Faccior-
usso et al. [29] mentioned that the mean time of nCLE proce-
dure was 6.094 minutes (4.91, 7.26, 95% CI).
Needle and probe should be manipulated with caution to
minimize disruption of the cyst epithelium (Statement 9).
Examining different foci within a cyst may be helpful for its
characterization. The FNA needle (preloaded with the nCLE
probe) should be carefully positioned within the cyst. The
nCLE probe should maintain a soft contact with the epithelium
of the cyst to obtain relevant images. After examining a specific
area of the cyst, the needle needs to be repositioned to exam-
▶Table 4 Diagnostic performance of EUS-nCLE for differentiating mucinous versus non-mucinous pancreatic cystic lesions (PCL) and serous cyst ade-
noma (SCA) versus non-SCA PCL.
Publica-
tion year
First author Study name N nDD
(surgery)
nCLE
yield
Mucinous versus non-mucinous PCL
SE SP PPV NPV ACC
2013 Konda, VJ. [27] INSPECT  66  57 (14)  89%  59%1 100%1 100%1  50%1 71%1
2015 Nakai, Y. [28] DETECT  30  18 (2) 100%  80% 100% 100%  80% 89%
2016 Napoleon, B. [9] CONTACT-I  33  20 (9)  90%  91%  95%  91%  95% 94%
2016 Karia, K. [32] AIRDPD  20   8 (3)  75% NA NA NA NA 46%
2017 Kadayifci, A. [12] CINE-Cyst  20  11 (5)  75%  66% 100% NA NA 83%
2018 Napoleon, B. [14] CONTACT-II 206  78 (39)  91%  95%2 100%2 100%2  94%2 97%2
2019 Krishna, S. G. [15] INDEX 144 113 (65) 100%  98%3
 96%4
 94%3
 95%4
 97%3
 96%4
 94%3
 93%4
97%3
97%4
SCA
SE SP PPV NPV ACC
2016 Napoleon, B. [9] CONTACT-I  33  20 (9)  90%  69% 100% 100%  82% 87%
2018 Napoleon, B. [14] CONTACT-II 206  78 (39)  91%  95%2 100%2 100%2  98%2 99%2
2019 Krishna, S. G. [15] INDEX 144 113 (65) 100% 100%3  97%3  50%3 100%3 97%3
EUS, endoscopic ultrasound; nCLE, needle-based confocal laser endomicroscopy; SE, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predic-
tive value; ACC, accuracy; NA, not available.
N represents the total number of patients
nDD represents patients with definitive diagnosis (histology from surgery and/or cytopathology)
Surgery is the number of patients with pancreatic surgery.
1 Calculated on a subpopulation of 31 patients (26 patients served for criteria identification)
2 Calculated on a subpopulation of 71 patients for which definitive diagnostic was reached either based on surgery or on cytohistology.
3 Calculated on a subpopulation of 113 patients for which definitive diagnostic was reached either based on surgery or on cytohistology
4 Calculated on a subpopulation of 65 patients for which definitive diagnostic was reached based on surgery
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Study year Events Total Sensitivity 95 % CI
Napoleon 2016 9 9 1.00 [0.66; 1.00]
Napoleon 2019 20 21 0.95 [0.76; 1.00]
Krishna 2020 19 22 0.86 [0.65; 0.97]
Random effects model   0.92 [0.81; 0.97]
Heterogeneity: I2 = 0 %, τ2 = 0, χ22 = 0.92 (P  = 0.63)
a
Study year Events Total Specifi city 95 % CI
Napoleon 2016 14 14 1.00 [0.77; 1.00]
Napoleon 2019 50 50 1.00 [0.93; 1.00]
Krishna 2020 91 92 0.99 [0.94; 1.00]
Random effects model   0.99 [0.96; 1.00]
Heterogeneity: I2 = 0 %, τ2 = 0, χ22 = 0.00 (P = 1.00)
c
Study year Events Total Negative predictive value 95 % CI
Napoleon 2016 14 14 1.00 [0.77; 1.00]
Napoleon 2019 50 51 0.98 [0.90; 1.00]
Krishna 2020 91 94 0.97 [0.91; 0.99]
Random effects model   0.97 [0.93; 0.99]
Heterogeneity: I2 = 0 %, τ2 = 0, χ22 = 0.18 (P  = 0.91)
b
Sensitivity
Specifi city
Negative predictive value
Study year Events Total Accuracy 95% CI
Napoleon 2016 23 23 1.00 [0.85; 1.00]
Napoleon 2019 70 71 0.99 [0.92; 1.00]
Krishna 2020 110 114 0.96 [0.91; 0.99]
Random effects model   0.98 [0.94; 0.99]
Heterogeneity: I2 = 0 %, τ2 = 0, χ22 = 0.69 (P  = 0.71)
e
Accuracy
 Experimental Control
Study Events Total Events Total Odds ratio OR 95 % CI
Napoleon 2016 9 9 0 14  551.000 [10.048; 30215.894]
Napoleon 2019 20 20 1 51  1380.333 [53.978; 35298.089]
Krishna 2020 19 20 3 94  576.333 [56.835; 5844.303]
Random effects model  49  159  727.964 [132.287; 4005.934]
Heterogeneity: I2 = 0 %, τ2 = 0, P  = 0.90
f
Diagnostic odds ratio
Study year Events Total Positive predictive value 95 % CI
Napoleon 2016 9 9 1.00 [0.66; 1.00]
Napoleon 2019 20 20 1.00 [0.83; 1.00]
Krishna 2020 19 20 0.95 [0.75; 1.00]
Random effects model   0.98 [0.87; 1.00]
Heterogeneity: I2 = 0 %, τ2 = 0, χ22 = 0.00 (P = 1.00)
d
Positive predictive value
0.8
0.8
0.8
0.8
0.8
0.4
0.4
0.4
0.4
0.4
0.6
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Specifi city
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1
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Diagnostic odds ratio
▶ Fig. 5 Needle-based confocal laser endomicroscopy a pooled sensitivity, b specificity, c negative predictive value, d positive predictive value,
e accuracy, and f diagnostic odds ratio for mucinous lesion diagnosis. OR, odds ratio.
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Study year Events Total Sensitivity 95 % CI
Konda 2013 13 22 0.59 [0.36; 0.79]
Nakai 2015 13 17 0.76 [0.50; 0.93]
Napoleon 2016 10 10 1.00 [0.69; 1.00]
Kadayifci 2017 8 12 0.67 [0.35; 0.90]
Napoleon 2019 38 40 0.95 [0.83; 0.99]
Krishna 2020 68 71 0.96 [0.88; 0.99]
Random effects model   0.87 [0.70; 0.95]
Heterogeneity: I2 = 76 %, τ2 = 1.2635, χ25 = 20.19 (P < 0.01)
a
Study year Events Total Specifi city 95 % CI
Konda 2013 9 9 1.00 [0.66; 1.00]
Nakai 2015 13 13 1.00 [0.75; 1.00]
Napoleon 2016 12 13 0.92 [0.64; 1.00]
Kadayifci 2017 6 6 1.00 [0.54; 1.00]
Napoleon 2019 31 31 1.00 [0.89; 1.00]
Krishna 2020 40 42 0.95 [0.84; 0.99]
Random effects model   0.97 [0.92; 0.99]
Heterogeneity: I2 = 0 %, τ2 = 0, χ25 = 0.16 (P = 1.00)
c
Study year Events Total Negative predictive value 95 % CI
Konda 2013 9 18 0.50 [0.26; 0.74]
Nakai 2015 13 17 0.76 [0.50; 0.93]
Napoleon 2016 12 12 1.00 [0.74; 1.00]
Kadayifci 2017 6 10 0.60 [0.26; 0.88]
Napoleon 2019 31 33 0.94 [0.80; 0.99]
Krishna 2020 40 43 0.93 [0.81; 0.99]
Random effects model   0.85 [0.65; 0.94]
Heterogeneity: I2 = 76 %, τ2 = 1.3136, χ25 = 17.83 (P<0.01)
b
Sensitivity
Specifi city
Negative predictive value
Study year Events Total Positive predictive value 95 % CI
Konda 2013 13 13 1.00 [0.75; 1.00]
Nakai 2015 13 13 1.00 [0.75; 1.00]
Napoleon 2016 10 11 0.91 [0.59; 1.00]
Kadayifci 2017 8 8 1.00 [0.63; 1.00]
Napoleon 2019 38 38 1.00 [0.91; 1.00]
Krishna 2020 68 70 0.97 [0.90; 1.00]
Random effects model   0.98 [0.94; 0.99]
Heterogeneity: I2 = 0 %, τ2 = 0, χ25 = 0.93 (P = 0.97)
d
Positive predictive value
0.8
0.8
0.8
0.8
0.4
0.4
0.4
0.4
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▶ Fig. 6 Needle-based confocal laser endomicroscopy a pooled sensitivity, b specificity, c negative predictive value, d positive predictive
value, e accuracy, and f diagnostic odds ratio for serous cystadenoma diagnosis. OR, odds ratio. Continuation see next page
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ine another area of the cyst wall. While repositioning, “brush-
ing” the cyst wall with the needle tip/probe can potentially
damage the membrane wall or vessels and cause bleeding.
Krishna et al. [10] underlined the difficulty to assess the whole
inside wall of a cyst with a 19G needle. However, the authors
felt confident that approximately 30% of the intra-cystic epi-
thelium in a two-dimensional plane could be comfortably visu-
alized [10].
Study year Events Total Accuracy 95 % CI
Konda 2013 22 31 0.71 [0.52; 0.86]
Nakai 2015 26 30 0.87 [0.69; 0.96]
Napoleon 2016 22 23 0.96 [0.78; 1.00]
Kadayifci 2017 14 18 0.78 [0.52; 0.94]
Napoleon 2019 69 71 0.97 [0.90; 1.00]
Krishna 2020 108 113 0.96 [0.90; 0.99]
Random effects model   0.91 [0.81; 0.96]
Heterogeneity: I2 = 71 %, τ2 = 0.7682, χ25 = 20.84 (P<0.01)
e
 Experimental Control
Study Events Total Events Total Odds ratio OR 95 % CI
Konda 2013 13 13 9 18  27.000 [1.396; 522.331]
Nakai 2015 13 13 4 17  81.000 [3.963; 1655.753]
Napoleon 2016 10 11 0 12  175.000 [6.428; 4764.193]
Kadayifci 2017 8 8 4 10  24.556 [1.112; 542.406]
Napoleon 2019 38 38 2 33  970.200 [44.918; 20955.591]
Krishna 2020 68 70 3 43  453.333 [72.625; 2829.770]
Random effects model  153  133  159.468 [49.088; 518.051]
Heterogeneity: I2 = 10 %, τ2 = 0.2210, P  = 0.35
f
Accuracy
Diagnostic odds ratio
0.8
100010
0.4
0.001 0.1
0.6
1
Accuracy
Diagnostic odds ratio
10.2
Fig. 6 Continuation.
▶Table 5 Interobserver agreement (IOA) of endoscopic ultrasound-guided, needle-based confocal endomicroscopy for evaluation of pancreatic
cystic lesions (PCL).
Publi-
cation
year
First
author
Study
name
N nDD
(sur-
gery)
Reviewers
#
Global IOA Mucinous
(IPMN or
MCN)
Bright parti-
cles on a dark
background
(pseudocyst)
Superficial
vascular
network
(SCA)
2016 Napoleon,
B. [9]
CONTACT-I 33 20 (9) 4 blinded 0.72
(0.52–0.87)
0.56
(0.23–0.82)
1.00
(1.00–1.00)
0.88
(0.68–1.00)
2016 Krishna,
S. G. [34]
INDEX 26 26 (23) 6 blinded NA 0.66
(0.56–0.76)
0.79
(0.69–0.89)
0.70
(0.60–0.80)
2017 Krishna,
S. G.[10]
INDEX 29 29 (23) 6 blinded
experts
NA NA 0.79
(0.70–0.88)
0.83
(0.73–0.92)
2016 Karia, K.
[32]
AIRDPD 15 (3)  8 (3) 6 blinded 0.13 NA NA NA
N represents the total number of patients.
nDD is the number of patients with definitive diagnosis (histology from surgery and/or cytopathology)
Surgery is the number of patients with pancreatic surgery.
IOA, intrer-observer agreement; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; NA, not available; SCA: serous cystadenoma
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Onsite presence of cytopathologist can facilitate nCLE
image interpretation (Statement 10)
In the preliminary observational and pilot studies [3, 6, 9, 27,
34], gastrointestinal pathologists have been instrumental in
identifying and validating nCLE criteria for different types of
PCLs. Since the nCLE image patterns of specific PCLs have been
described and validated, an endoscopist with proper training
and credentialing should be able to accurately identify and in-
terpret the validated criteria with high IOA as reported in the
literature [9, 10, 32, 34] (▶Table 5). However, it might be help-
ful to partner with a pathologist during the initial learning curve
based on the individual interest of the pathologist and institu-
tional provisions.
Indications for EUS-nCLE
nCLE is indicated in patients with indeterminate non-
communicating cysts when EUS-FNA is performed
(Statement 11)
Currently, EUS-FNA with cyst fluid analysis is the standard of
care for evaluating PCLs but the accuracy (< 50%) is very low for
differential diagnosis of PCLs [19]. For this reason, the major
society guidelines for managing PCLs are controversial when it
comes to the value of cyst fluid analyses [39, 40]. Lack of clear
and undisputed guidelines is eventually reflected in incongru-
ent and suboptimal patient management across the globe
with superfluous imaging, endoscopy procedures or pancreatic
surgeries [41, 42].
In a recent study, the addition of nCLE to EUS-FNA with cyst
fluid analysis changed diagnosis and management strategy of
PCLs in nearly one-third of cases, while improving inter-observ-
er agreement [43]. In the INDEX study [13], nCLE and cyst fluid
molecular markers were complementary with a diagnostic ac-
curacy for mucinous-PCLs of 100% when applied in tandem.
Thus, performing nCLE for a PCL at the time of the index proce-
dure when EUS-FNA is performed could be advantageous by re-
ducing the number of follow-up procedures including repeat
EUS-FNA. This might lead to savings in healthcare resource uti-
lization [44].
nCLE is indicated when a pancreatic cyst remains indetermi-
nate at previous EUS-FNA (Statement 12).
In the CONTACT II [14] cohort, 67 of 206 patients had under-
gone a previous inconclusive EUS-FNA (inconclusive CEA, no cy-
tology). In these patients, nCLE was able to establish a diagnosis
in 61 cases (91%), while a repeat attempt at cytology per-
formed during the procedure was contributive in 25 cases
(37%) and CEA concentrations greater than 192ng/mL noticed
in 19 cases (28%).
Repeat nCLE on subsequent follow-up procedures should
not be routinely performed (Statement 13).
To date, there is no evidence in the literature supporting re-
peat nCLE during follow-up EUS. In the absence of clear-cut in-
dications (such as non-diagnostic nCLE and development of
new worrisome features) repeat EUS-nCLE should not be per-
formed on subsequent follow-up procedures.
Training and credentialing in EUS-nCLE
A consensus report based on clinical evidence for probe-based
confocal laser endomicroscopy (pCLE) use has been published
for gastrointestinal [16]. Some statements have already been
described and are applicable to nCLE. We propose complemen-
tary statements specific to EUS-nCLE (4–1 to 4–3).
Physicians are expected to have a good understanding of
pancreatic cystic lesions, and procedural indications and
contraindications for EUS-nCLE (Statement 14).
In order to maximize the outcomes of the procedure and
execute it safely, the physician must weigh the benefits versus
▶Table 6 nCLE procedure adverse events.
First author Study name N nCLE mean
duration
(minutes)
Pancreatitis
rate (%) with
95% CI
Intracystic
bleeding (%)
with 95% CI
Global adverse events
(%) With 95% CI
2013 Konda, VJ. [27] INSPECT  66  6 3.0% 0.0% 3.0%
2015 Nakai, Y. [28] DETECT  30 101 6.6% 0.0% 6.6%
2016 Napoleon, B. [9] CONTACT-I  33  7 3.0% 0.0% 3.0%
2016 Karia, K. [32] AIRDPD  15  2 0.0% 0.0% 0.0%
2020 Krishna, S. G. [15] INDEX 144  7.3 4.9% 0.0% 4.9%
2017 Kadayifci, A. [12] CINE-Cyst  20  6 0.0% 0.0% 0.0%
2019 Napoleon, B. [14] CONTACT-II 206  5 1.5% 3.88% 5.23%
Total
(95% CI)
514  6.2
(4.3–8.1)
2.92%
(1.6%–5.0%)
0.7 %
(0%–3.6%)
4.50%
(3.0%–6.6%)
N represents the total number of patients.
nCLE, needle-based confocal laser endomicroscopy.
1 for Nakai et al [28] nCLE procedure time had a mean of 6 minutes followed by cystoscopy with mean duration of 4 minutes
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risks and proceed with nCLE only when indicated for an eligible
patient, under optimal conditions.
Trainees in EUS-nCLE of PCLs need to be fully competent in
pancreatic EUS and EUS-FNA (Statement 15).
nCLE is considered to be an advanced endoscopic imaging
technique. Before starting with nCLE, physicians are expected
to have completed training in EUS and EUS-FNA (advanced
endoscopy training) with appropriate credentialing in addition
to a standard gastroenterology fellowship or specialty program.
Trainees should learn how to obtain optimal nCLE images
of the intracystic epithelium to achieve satisfactory images
(Statement 16).
During EUS-nCLE, the probe must be positioned in tight con-
tact with the intracystic epithelium at a perpendicular or slight-
Study year Events Total Event rate 95% CI
Konda 2013 0 66 0.000 [0.000; 0.054]
Nakai 2015 0 30 0.000 [0.000; 0.116]
Napoleon 2016 0 33 0.000 [0.000; 0.106]
Karia 2016 0 15 0.000 [0.000; 0.218]
Kadayifci 2017 0 20 0.000 [0.000; 0.168]
Napoleon 2019 8 206 0.039 [0.017; 0.075]
Krishna 2020 0 144 0.000 [0.000; 0.025]
Random effects model   0.001 [0.000; 0.360]
Heterogeneity: I2 = 85 %, τ2 = 6.8547, χ26 = 0.00 (P = 1.00)
a
Study year Events Total Event rate 95% CI
Konda 2013 2 66 0.030 [0.004; 0.105]
Nakai 2015 2 30 0.067 [0.008; 0.221]
Napoleon 2016 1 33 0.030 [0.001; 0.158]
Karia 2016 0 15 0.000 [0.000; 0.218]
Kadayifci 2017 0 20 0.000 [0.000; 0.168]
Napoleon 2019 3 206 0.015 [0.003; 0.042]
Krishna 2020 7 144 0.049 [0.020; 0.098]
Random effects model   0.029 [0.016; 0.050]
Heterogeneity: I2 = 9 %, τ2 = 0.0549, χ26 = 4.07 (P = 0.67)
b
Study year Events Total Event rate 95% CI
Konda 2013 2 66 0.030 [0.004; 0.105]
Nakai 2015 2 30 0.067 [0.008; 0.221]
Napoleon 2016 1 33 0.030 [0.001; 0.158]
Karia 2016 0 15 0.000 [0.000; 0.218]
Kadayifci 2017 0 20 0.000 [0.000; 0.168]
Napoleon 2019 11 206 0.053 [0.027; 0.094]
Krishna 2020 7 144 0.049 [0.020; 0.098]
Random effects model   0.045 [0.030; 0.066]
Heterogeneity: I2 = 0 %, τ2 = 0, χ26 = 1.01 (P = 0.99)
c
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▶ Fig. 7 Needle-based confocal laser endomicroscopy pooled adverse event rates: a intracystic bleeding rate, b pancreatitis rate, and c global
event rate.
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ly tangential angle. Because scope maneuvering and duration
of the examination can influence risk of post-procedural pan-
creatitis, trainees must master scope and needle control to
minimize risks.
Discussion
A major hurdle in management of PCLs is accurate and reliable
differentiation of pre-malignant or neoplastic lesions (muci-
nous PCLs, cystic-NENs) from benign PCLs (SCA, pseudocysts).
Only patients with mucinous PCLs need to be followed accord-
ing to the Fukuoka Consensus Guidelines (2012 and 2017 revi-
sion) [45]. With these aspects in mind, our international nCLE
group has developed a consensus to help practicing clinicians
use a novel diagnostic modality with high diagnostic accuracy
(EUS-nCLE) when managing patients with PCLs.
The methodology of this consensus report involved a thor-
ough literature search performed by experts in pancreatology
and/or endomicroscopy involving all the published literature
evaluating EUS-nCLE in the management of PCLs. A structured
methodology was used to develop the consensus statements.
Adoption of a statement was based on the agreement level vo-
ted by the panelists. The grade of evidence was also assessed
for each statement. The four group leaders provided up-to-
date literature to the participants, who undertook responsibil-
ity for voting based on their individual expertise and appraisal
of the literature.
The consensus process resulted in a high level of agreement
for the majority of the statements. This suggests that in de-
fined circumstances, there is ample clinical evidence for an ad-
ded benefit of application of nCLE in management of PCLs.
First, EUS-nCLE provides better differentiation of mucinous
and non-mucinous PCLs compared to the current standard of
care. Second, EUS-nCLE can improve the accuracy of diagnosis
of SCAs, thus reducing the rate of unnecessary follow-up inves-
tigations or inappropriate resections. Third, the interobserver
agreement for EUS-nCLE to differentiate mucinous from non-
mucinous PCLs is high.
Finally, EUS-nCLE is as safe as a currently used diagnostic
standard of care procedure, that is, EUS-guided FNA with a
19G needle. Further research is required to assess the cost-ef-
fectiveness of this approach.
The consensus panel recognizes the challenge of measuring
the benefit of specific interventions in assessment of learning.
Hands-on nCLE experience and cognitive training are manda-
tory during the initial training phase. Continued self-training is
recommended for better understanding and interpretation of
nCLE findings. This includes review of the literature, published
videos, online resources, and attending focused conferences.
The panel recommends a minimum number of 10 EUS-nCLE
procedures under supervision of an experienced operator to
achieve competency and the same number of EUS-nCLE proce-
dures performed per year to maintain competency. Because
these statements involving training are not based on scientific
evidence but on consensus agreement, formal prospective re-
search is necessary to validate these propositions.
There are a number of potential limitations to this study. The
first is the low number of studies addressing training in nCLE,
including the technical procedure and nuances of nCLE image
interpretation. Second, because data are lacking, we were un-
able to compare nCLE to more recent techniques for character-
izing PCLs, such as intracystic biopsies and molecular DNA anal-
ysis.
Despite these limitations, this report represents the most in-
clusive consensus paper available to date on EUS-nCLE for man-
agement of PCLs. The outcomes are clinically relevant and the
high degree of consensus disclosed for the majority of state-
ments makes a strong case for application of EUS-nCLE in clini-
cal practice. In addition, areas in which consensus was not
achieved were identified to direct future work and research ef-
forts.
Conclusions
This consensus established that EUS-guided nCLE is a minimally
invasive procedure that improves evaluation of PCLs. The rou-
tine addition of nCLE to standard EUS-FNA could positively im-
pact patient management and improve healthcare resource
utilization by reducing the number of misdiagnoses and pre-
venting redundant follow-up investigations and unnecessary
surgery. Structured training of endosonographers in this novel
technology for competent application is needed. Complemen-
tary research on cost-effectiveness and in areas where consen-
sus was not achieved is required.
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